Gordon Foulkes, PhD

Chief Executive Officer, Thesan Pharmaceuticals, Inc.

Dr. Gordon Foulkes has over 25 years of experience in biopharmaceutical Executive Management R&D and Venture Capital. Most recently, he served as the founding CEO of Excaliard Pharmaceuticals from 2007-2009, and resumed that role in 2010, to lead the acquisition of Excaliard by Pfizer in 2011. Dr. Foulkes also served as a Managing Director of RiverVest Ventures from 2005-2010. Previously, he headed R&D, and served on the Boards of multiple biotechnology companies, including Oncogene Science, Inc. (NASDAQ: OSIP; acquired by Astellas for $4 billion in 2010), Aurora Biosciences (NASDAQ: ABSC; acquired by Vertex for $590M in 2001), and Elitra Pharmaceuticals (acquired by Merck). Dr. Foulkes has had a lead role in securing more than 15 corporate partnerships, resulting in over $350 million in recognized revenues, as well as directly participated in raising over $215 million in private, IPO and follow-on public offerings. Prior to joining Industry, he held academic positions at both MIT and the Medical Research Council (UK).

Jay Birnbaum, PhD

Exec. Vice President Global Product Development

Dr. Jay Birnbaum is a dermatology consultant specializing in ethical and OTC drugs, devices, and cosmeceuticals. His 30+ years of industry experience span the areas of discovery research, formulation, clinical R&D, regulatory and marketing. He has been involved in the development and commercialization of numerous products, including Lamisil antifungal products (the world’s largest selling dermatology brand), Apligraf (the first bioengineered, living skin equivalent), and Skin Caviar (the centerpiece of the upscale LaPrairie Skin Care brand). Dr. Birnbaum was a co-founder and CMO of Kythera Biopharmaceuticals, a company developing products in aesthetic dermatology. Kythera (whose lead product is now in Ph3) recently completed a successful IPO(NASDAQ:KYTH). Prior to starting his own consulting company in 1999, Dr. Birnbaum was VP, Global Project Management at Novartis/Sandoz, and held management positions in the Medical and Consumer Product Divisions of American Cyanamid Company (Wyeth). Dr. Birnbaum has served as a member of the Board of Directors of Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) and Excaliard Pharmaceuticals (acquired by Pfizer in 2011), as well as the SABs of multiple companies. He received a B.S. degree from Trinity College and a Ph.D. in Pharmacology from the Univ. of Wisconsin.

Charlotte Merritt

Head of Regulatory Affairs

Ms. Charlotte Merritt has over 25 years of pharmaceutical industry experience focused on global regulatory strategy development, regulatory agency interface, regulatory business operations and organizational leadership. Her experience spans all phases of drug development and many therapeutic areas. Most recently, Ms. Merritt was an Executive Director of Global Regulatory Affairs at Merck & Co. where she contributed to the global registration of numerous important medical therapies (including Singulair®, Proscar®, Propecia®, and Emend®) and led many strategic and organizational transformation initiatives. Ms. Merritt received her BS in Biology from Albright College and her MBA from Washington University in St. Louis. She is a member of the Drug Information Association.

K. George Mooney, PhD

Exec. Vice President Pharmaceutical Sciences

Dr. George Mooney has over 30 years prior industrial experience, most recently as VP for the Exploratory Development Portfolio at Pfizer and VP of Pharmaceutical Sciences, Pfizer Europe. Other former companies include at GD Searle, Boehringer Ingelheim (USA) and American Cyanamid Co. Dr. Mooney has been associated with more than 30+ NDAs and over 80 IND filings. He qualified as a Pharmacist in the UK (B.Pharm, MSc University of London) and gained his PhD at University of Kansas in Pharmaceutical Sciences. He is a William Pitt Fellow at Pembroke College Cambridge UK, a member of the American Association of Pharmaceutical Scientists and of the Royal Pharmaceutical Society of Great Britain.

Howard Welgus, MD

Chief Medical Officer

Dr. Howard Welgus is a board-certified dermatologist. Most recently Dr. Welgus was the VP R&D and CMO for Nycomed U.S. (Fougera / PharmaDerm). From 1999 to 2009, Dr. Welgus served as VP R&D for both the Dermatology and Inflammation Therapeutic Areas of Warner Lambert and then Pfizer. In this capacity, he led a team of almost 200 R&D colleagues, moving ten dermatology compounds and nine arthritis compounds into clinical development and shepherded them through key proof of concept trials. Dr. Welgus received his medical, scientific and dermatology training at Washington University School of Medicine, and had served as Professor and Chief of Dermatology at both Barnes-Jewish Hospital and the Washington University School of Medicine. Dr. Welgus has published over 120 original scientific articles.

Shawna Miller

Director of Finance

Ms. Shawna Miller has nearly 20 years of experience working in various positions in multiple biotechnology companies, including financial, office management and information technologies. Most recently as Controller at Excaliard Pharmaceuticals, Inc. (2007 – 2011) where she participated in the successful acquisition by Pfizer. Ms. Miller worked at the Accounting Manager for Althea Technologies, Inc., (2004 – 2006), Elitra Pharmaceuticals, Inc. (1999 – 2004), Clinical Operations Coordinator for Alliance Pharmaceutical Corp, San Diego (1995 – 1998). Ms Miller has a Bachelors in Business Administration and Management from the University of Redlands, Redlands California.